Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.34 |
| ▸ | ICMT | O60725 | 11/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28935680 | 0.89 | L3MBTL1 (0.46) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL12631148 | 0.89 | PTGDR2 (0.48) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL1995369 | 0.86 | L3MBTL1 (0.49) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL1998282 | 0.84 | L3MBTL1 (0.65) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL28935632 | 0.83 | HTR6 (0.39) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL11948700 | 0.82 | L3MBTL1 (0.43) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL1994265 | 0.80 | PTGDR2 (0.42) | PTGDR2FABP4PLA2G2AICMT | |
| SCHEMBL28935728 | 0.78 | L3MBTL1 (0.41) | L3MBTL1HTR6EPHX1PTGDR2BCHE | |
| SCHEMBL30777140 | 0.77 | L3MBTL1 (0.72) | L3MBTL1HTR6EPHX1FABP4ICMT | |
| SCHEMBL12631144 | 0.74 | BCHE (0.36) | L3MBTL1HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | L3MBTL1 3898/4885HTR6 368/4885EPHX1 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.